Abstracts Archive - Page 859 of 2607 - ACR Meeting Abstracts

Abstract Number: 0339 • ACR Convergence 2020
Is Sex-adjusted Treatment in Early-PsA Justified?
Evangelia Passia¹, Jolanda Luime¹, Marc Kok², Ilja Tchetverikov³, Marijn Vis⁴, Fouchia Fodili⁵, Yvonne Ruiterman⁶ and Lindy-Anne Korswagen⁷, ¹Erasmus MC, Rotterdam, ²Maasstadziekenhuis, Rotterdam, ³Albert Schweitzer Ziekenhuis, Dordrecht, ⁴Erasmus UMC, Rotterdam, Netherlands, ⁵RZWN, Roosendaal, ⁶HAGA ziekenhuis, Den Haag, ⁷Franciscus Gasthuis, Rotterdam
Background/Purpose: According to existing knowledge, the prevalence of psoriatic arthritis (PsA) is equal in men and women, however, women experience a higher burden of disease…
Abstract Number: 0340 • ACR Convergence 2020
Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity
Maria Elisa Acosta¹, Olga Compán², Sonia Pastor¹, Guadalupe Manzano Canabal¹, Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Olga Martinez Gonzalez⁵, Ana Isabel Turrión¹, Javier Del Pino-Montes¹ and Carlos Montilla Morales¹, ¹Hospital Universitario de Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, ´Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In psoriatic arthritis (PsA) peripheral nociceptive pain is characteristic, and is trigger by the activation of the afferent sensory fibers in the inflamed synovial…
Abstract Number: 0341 • ACR Convergence 2020
Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity
Wei Han¹, Xiaohang Wang¹, Liang Li¹, Stephanie Wichuk², Edna Hutchings³, Rana Dadashova³, Joel Paschke³ and Walter Maksymowych², ¹Department of Chemistry, University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, AB, Canada, ³CARE Arthritis, Edmonton, AB, Canada
Background/Purpose: In this work, we applied a high-performance chemical isotope labeling (CIL) LC-MS platform to search for biomarker candidates of PsA and AS in human…
Abstract Number: 0342 • ACR Convergence 2020
Multimorbidity Clusters in Psoriatic Arthritis: A Population-Based Study
Paras Karmacharya¹, Dilli Poudel², Cynthia Crowson³, John Davis⁴, Kerry Wright⁴ and Alexis Ogdie², ¹Mayo Clinic, Rochester MN, ROCHESTER, MN, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Psoriatic arthritis (PsA) patients have a higher prevalence of cardiometabolic and other morbidities compared to the general population. Studies suggest that a single clinical…
Abstract Number: 0343 • ACR Convergence 2020
Co-expression of DC-STAMP and CX3CR1: Biomarkers for Tissue Resident Osteoclasts in Psoriatic Arthritis
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno², Ananta Paine³, Benjamin Korman³, Marc Nuzzo⁴, Lihi Eder⁵ and Christopher Ritchlin³, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY, ³Department of Medicine, University of Rochester Medical Center, Rochester, NY, ⁴Department of Medicine, University of Rochester Medical Center, Rochester, ⁵Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) patients often experience joint damage mediated by osteoclasts (OC). Although PsA pathogenesis is poorly understood, the production of the cytokines IL-17,…
Abstract Number: 0344 • ACR Convergence 2020
Use of the BASDAI in Psoriatic Arthritis Patients with and Without Axial Disease
Soumya Reddy¹, M. Elaine Husni², Jose Scher³, Ethan Craig⁴, Alexis Ogdie⁴ and Jessica Walsh⁵, ¹NYU School of Medicine, New York, NY, ²Cleveland Clinic, Cleveland, OH, ³NYU School of Medicine, New York City, ⁴University of Pennsylvania, Philadelphia, PA, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is increasingly being used to assess the activity of axial disease in patients with psoriatic arthritis…
Abstract Number: 0345 • ACR Convergence 2020
Effectiveness and Safety of Apremilast in Biologic-Naive versus Biologic-Experienced Patients with Psoriatic Arthritis in Real-World Clinical Practice Settings in Germany: Interim Analysis of an Ongoing, Multicenter, Prospective, Non-interventional Study
Jurgen Wollenhaupt¹, Christian Bach² and Josefine Roemmler-Zehrer³, ¹Rheumatologie im Struenseehaus, Hamburg, Germany, ²Amgen GmbH, München, Germany, ³Amgen GmbH, München
Background/Purpose: Apremilast (APR) was associated with improvements in physician-assessed and patient-reported outcomes in a large cohort of patients with PsA based on a 1-year interim…
Abstract Number: 0346 • ACR Convergence 2020
Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
Philip Mease¹, Josef Smolen², Arthur Kavanaugh³, Peter Nash⁴, Gaia Gallo⁵, Soyi Liu-Leage⁵, Christophe Sapin⁵ and Mark Genovese⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ³UC San Diego Health System, San Diego, CA, ⁴School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Ixekizumab (IXE) was shown to be superior to adalimumab (ADA) in achievement of simultaneous improvement of joint and skin disease (American college of Rheumatology…
Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Proton Rahman¹, Philip Helliwell², Atul Deodhar³, Alexa Kollmeier⁴, Elizabeth Hsia⁵, Bei Zhou⁶, Xiwu Lin⁶, Chenglong Han⁶ and Philip Mease⁷, ¹Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…
Abstract Number: 0348 • ACR Convergence 2020
Biologics History and Sex Are Linked to Golimumab Discontinuation in Axial Spondyloarthritis: A Sub-Analysis of the Post-Registration GO-Practice Study
Philippe Bertin¹, Philippe Goupille², Florence Tubach³, Eric Lespessailles⁴, Naoual Harid⁵, Saannya Sequeira⁶, Jean-Marie Fayette⁶, Bruno Fautrel⁷ and Rene-Marc Flipo⁸, ¹Limoges University Hospital, Limoges, France, ²CHU Tours, department of rheumatology, Tours, France, ³Pierre Louis Institute of Epidemiology and Public Health, INSERM 1136, Sorbonne University and Centre of Pharmacoepidemiology, Pitié Salpêtrière Hospital, APHP.Sorbonne University, Paris, Ile-de-France, France, ⁴Regional Hospital and University of Orleans, Orléans, France, ⁵MSD France Puteaux, Puteaux, Ile-de-France, France, ⁶ClinSearch, Malakoff, Ile-de-France, France, ⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ⁸Lille University Hospital, Lille, France
Background/Purpose: Golimumab (GLM) is the latest anti-TNFα to be indicated for treating rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The post-registration GO-PRACTICE…
Abstract Number: 0349 • ACR Convergence 2020
Pooled Safety Results from Two Phase-3 Trials of Guselkumab in Patients with Psoriatic Arthritis Through 1 Year
Christopher Ritchlin¹, Proton Rahman², Philip Helliwell³, Wolf-Henning Boehncke⁴, Iain McInnes⁵, Alice Gottlieb⁶, Shelly Kafka⁷, Alexa Kollmeier⁸, Elizabeth Hsia⁹, Xie Xu¹⁰, May Shawi¹¹, Shihong Sheng¹², Prasheen Agarwal¹², Bei Zhou¹², Paraneedharan Ramachandran¹³ and Philip Mease¹⁴, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Geneva University Hospitals, Geneva, Switzerland, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ¹⁰Janssen Research & Development, LLC, San Marcos, CA, ¹¹Janssen Global Services, LLC, Toronto, ON, Canada, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Janssen Research & Development, LLC, Horsham, ¹⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2, two double-blind, phase 3, psoriatic arthritis (PsA) trials of guselkumab (GUS, an IL-23 inhibitor), demonstrated significant improvement with GUS vs…
Abstract Number: 0350 • ACR Convergence 2020
The Impact of Age and Time Since Diagnosis on Response to Treatment with Secukinumab in Pooled Week 52 Data from 4 Phase 3 Studies in Patients with Ankylosing Spondylitis
Atul Deodhar¹, Philip Mease², Paula Machado³, Effie Pournara⁴, Xiangyi Meng³, Vibeke Strand⁵ and Marina Magrey⁶, ¹Oregon Health & Science University, Portland, OR, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ⁶Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease involving the sacroiliac joints and spine and associated with pain, stiffness, and disability.1 A previous analysis…
Abstract Number: 0351 • ACR Convergence 2020
Ustekinumab-Treated Patients with Psoriatic Arthritis in a Real-world Study: Similar Clinical Responses and Treatment Persistence over One Year in Elderly and Younger Patients
Laure Gossec¹, Elke Theander², Soumya Chakravarty³, Paul Bergmans⁴, Iris Lin⁵, Wim Noël⁶, Stefan Siebert⁷ and Josef Smolen⁸, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²Janssen Cilag, Lund, Sweden, ³Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁴Janssen Biostatistics and Medical Affairs, Tilburg, Netherlands, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Janssen Medical Affairs, LLC, Beerse, Belgium, ⁷University of Glasgow, Glasgow, United Kingdom, ⁸Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
Background/Purpose: In the PsABio study (NCT02627768), real-world data from patients with PsA showed comparable clinical results after treatment with ustekinumab (UST, an anti-p40 IL-12/23 inhibitor)…
Abstract Number: 0352 • ACR Convergence 2020
Efficacy and Safety of Ixekizumab versus Adalimumab with and Without Concomitant Conventional Synthetic Disease-Modifying Antirheumatic Drugs (DMARD) in Biologic DMARD-Naïve Patients with Psoriatic Arthritis: 52-Week Results
Josef Smolen¹, Anthony Sebba², Eric Ruderman³, Amanda Gellett⁴, Christophe Sapin⁴, Aubrey Sprabery⁴, Soyi Liu-Leage⁴, Sreekumar Pillai⁴, Paulo Reis⁴ and Peter Nash⁵, ¹Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, ²Arthritis Associates, Palm Harbor, Tampa, FL, ³Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵School of Medicine Griffith University, Brisbane, Queensland, Australia
Background/Purpose: Ixekizumab (IXE), a high-affinity monoclonal antibody selectively targeting IL-17A, was superior to adalimumab (ADA) at Week (Wk) 24 for simultaneous achievement of ACR50 and…
Abstract Number: 0353 • ACR Convergence 2020
Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Laura Coates¹, Philip Mease², Dafna Gladman³, Sandra Navarra⁴, Weibin Bao⁵ and Corine Gaillez⁶, ¹University of Oxford, Oxford, United Kingdom, ²Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of Santo Tomas, Manila, Philippines, ⁵Novartis Pharmaceuticals Corporation, East Hannover, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: A treat-to-target approach in psoriatic arthritis (PsA) was recommended by EULAR and GRAPPA to achieve remission (REM) or low disease activity (LDA), by regular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].